## Targeting HLA-DRB1: A Novel CAR T-Cell Therapy Approach for Relapsed Acute Myeloid Leukemia
Acute myeloid leukemia (AML) remains a formidable challenge in oncology, often returning even after aggressive treatments like allogeneic hematopoietic stem cell transplantation (allo-HCT). The core difficulty in developing effective anti-cancer therapies lies in selectively eliminating malignant cells while sparing healthy tissue. Identifying targets uniquely expressed by cancer cells is paramount, but proving notably elusive in AML. Now, groundbreaking research published in *Nature Cancer* offers a promising new avenue: targeting a molecule called HLA-DRB1 with chimeric antigen receptor (CAR) T-cell therapy. This approach could offer a lifeline to AML patients who have relapsed following allo-HCT.
### The Challenge of AML and the promise of CAR T-Cell Therapy
AML is a cancer of the blood and bone marrow characterized by the rapid growth of abnormal white blood cells. While allo-HCT – a procedure involving stem cell transplantation from a donor – can induce remission,relapse rates remain meaningful. This underscores the urgent need for innovative therapies that can overcome the disease’s resilience.
CAR T-cell therapy has revolutionized the treatment of certain blood cancers, notably B-cell leukemia/lymphoma and multiple myeloma. This powerful immunotherapy involves genetically engineering a patient’s T cells to express a chimeric antigen receptor (CAR). This CAR allows the T cells to recognize and destroy cancer cells expressing a specific target antigen. Though, a major hurdle in applying CAR T-cell therapy to AML is identifying targets that are *exclusively* found on leukemia cells.Many potential targets are also present on normal cells, raising the risk of debilitating and potentially life-threatening toxicity.
### Identifying HLA-DRB1 as a Potential AML Target
Researchers at The University of Osaka, leading a multi-institutional team, employed a clever strategy to circumvent this challenge. Building on their previous success in multiple myeloma, they screened thousands of monoclonal antibodies (mAbs) – laboratory-produced antibodies designed to bind to specific targets – to identify those that reacted with AML cells but not with healthy blood cells.
This meticulous screening process narrowed the field to 32 promising mAbs. One, designated KG2032, stood out, demonstrating binding to AML cells in over 50% of patient samples. Further examination, utilizing advanced sequencing techniques, revealed that KG2032 specifically binds to a variant of the HLA-DRB1 molecule.
“Interestingly,we found that KG2032 reacted with a specific HLA-DRB1 subset in which the protein has an amino acid other then aspartic acid in the 86th position,” explains Naoki Hosen,senior author of the study. This is a crucial finding. KG2032’s reactivity is contingent on a mismatch between the patient and their allo-HCT donor. specifically, the patient must carry the HLA-DRB1 variant with the non-aspartic acid residue, while the donor does not. This specificity dramatically reduces the potential for off-target effects on healthy tissues.
### Promising Results *In Vitro* and *In Vivo*
To validate their findings, the researchers engineered CAR T cells expressing the KG2032 antibody. These CAR T cells demonstrated potent and selective anti-AML activity in laboratory settings (*in vitro*). Crucially, they also exhibited significant efficacy in a mouse model of AML (*in vivo*), effectively targeting and eliminating leukemia cells. Importantly, the treated mice showed no signs of significant toxicity, bolstering the safety profile of this approach.
The team also explored the potential of CAR natural killer (NK) cells, another type of immune cell, engineered with KG2032. These CAR NK cells mirrored the positive results observed with CAR T cells, further expanding the therapeutic possibilities.
### What This Means for AML Patients
These findings represent a significant step forward in the development of targeted therapies for AML. By exploiting the HLA-DRB1 mismatch between patient and donor, this approach offers a potential solution to the challenge of identifying truly cancer-specific targets. The ability to engineer both CAR T cells and CAR NK cells provides flexibility and potentially broadens the applicability of this therapy.
The research team is now actively planning clinical trials to evaluate the safety and efficacy of KG2032-derived CAR T and NK cell therapies in AML patients who have relapsed after allo-HCT. This innovative strategy holds the promise of transforming the treatment landscape for this aggressive cancer, offering renewed hope to patients facing a arduous prognosis.
—
### Evergreen Section: The Future of Personalized Immunotherapy in AML
The success of targeting HLA-DRB1 highlights a
